Transcriptional profiling of patient-derived xenograft models of myxoid liposarcoma either responsive or resistant to trabectedin treatment.

ABSTRACT: Transcriptional profiling of patient-derived xenograft models of myxoid liposarcoma with either FUS-CHOP type I, named as ML017, or FUS-CHOP type III, named as ML006. Both ML017 and ML006 are responsive to trabectedin treatment, while model ML017/ET has aquired resistance to the drug. Samples are either under untreated conditions, or treated either with trabectedin or pioglitazone or both.

ORGANISM(S): Homo sapiens

SUBMITTER: Laura Mannarino 

PROVIDER: E-MTAB-8632 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress